Detection of hMSH2 and hMLH1 mutations in Chinese hereditary non-polyposis colorectal cancer kindreds

Chang-Hua Zhang, Yu-Long He, Fang-Jin Wang, Wu Song, Xi-Yu Yuan, Dong-Jie Yang, Chuang-Qi Chen, Shi-Rong Cai, Wen-Hua Zhan

AIM: To establish and validate the mutation testing for identification and characterization of hereditary non-polyposis colorectal cancer (HNPCC) in suspected Chinese patients.

RESULTS: Mutations were identified in two Chinese HNPCC kindreds. One was the missense mutation of hMSH2 c.1808A→G resulting in Asp 603 Gly identified in the proband of the fifth HNPCC (HNPCC5) kindred. In the HNP5 kindred, three family members were found to have this mutation and two of them had colorectal cancer. The other mutation of hMLH1 c.1882A→G was identified in the HNP2 kindred's proband, which might be the nonsense mutation analyzed by BLAST.

CONCLUSION: Pedigree investigation and mutation testing of hMSH2 and hMLH1 are the practical methods to identify high-risk HNPCC patients in China.

Key words: Screening; Human mutS homology 2 gene; Human mutL homology 1 gene; Colorectal cancer; Heredity

http://dx.doi.org/10.3748/wjg.14.298

INTRODUCTION

Hereditary non-polyposis colorectal cancer (HNPCC) syndrome is characterized by autosomal-dominantly inherited predisposition to early colorectal carcinoma and extracolonic epithelia-derived tumors most often located in the gastrointestinal and urogenital tracts[3]. The mean age of HNPCC and sporadic colorectal cancer (CRC) patients at diagnosis is 42 years and 65 years, respectively. HNPCC, accounting for approximately 5%-15% of all CRCs, is categorized as Lynch I or Lynch II syndrome (according to revised Amsterdam criteria)[2]. Germline mutations of the mismatch repair (MMR) genes identified in HNPCC kindreds, including MSH2, MLH1, MSH6, PMS1 (promotion of mutS homology 1), PMS2, and MLH3, have been proved as the major cause for HNPCC by linkage analysis. Mutations in two of these MMR genes, MSH2 and MLH1, account for the majority of the kindreds with HNPCC[3]. Thus, pedigree investigation and MMR gene testing, as the basis for efficient prevention and treatment of HNPCC, are most often used in early diagnosis of at-risk family members and in confirmation of the diagnosis of HNPCC.

CRC is the third life-threatening cancer in China. However, HNPCC pedigree and its predisposition gene have not been extensively studied. We have established a CRC database since 1994 and the follow-up rate is above 90%. We have recently paid attention to hereditary colorectal cancer in South China and found that about 3% of the diagnosis of CRC patients have multiple CRCs to which the young are vulnerable[3]. Thus, we collected those CRC families and finally obtained eleven independent Chinese kindreds with HNPCC by deep pedigree investigation until January,
2004. Five of them fulfilled the classical Amsterdam criteria. To identify high-risk populations with HNPCC, we tested hMSH2 and hMLH1 mutations in these classical kindreds.

**MATERIALS AND METHODS**

**Patients**

The clinical diagnosis of classical HNPCC was established and verified at the Department of Gastrointestinopancreatic surgery, the First Affiliated Hospital of the Sun Yat-Sen University\(^5\). Five independent Chinese kindreds with HNPCC fulfilling the classical Amsterdam criteria were collected. The study was approved by the Ethical Committee of Sun Yat-Sen University.

**DNA isolation**

Peripheral blood samples were collected from both patients and their family members in each Chinese kindred after informed consent was obtained for genetic analysis. DNA was extracted directly from leukocytes following the standard procedures.

All exons of MLH1 and MSH2 were amplified for mutation testing. Samples were used to amplify in 20 mL reaction volume containing approximately 100 ng DNA in 50 mmol/L KCl, 10 mmol/L Tris-HCl, 1.5 mmol/L MgCl\(_2\), 200 mmol/L each dNTP, 0.01% gelatin, 1 U Taq-polymerase, and 20-40 pmol each primer. The PCR amplification conditions were as follows: denaturation at 95°C for 5 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at fragment-specific annealing temperature for 1 min, extension at 72°C for 1 min, and a final extension at 72°C for 7 min. The primers, annealing temperature, and size of the PCR products for each of the investigated hMLH1 and hMSH2 exons are described elsewhere\(^6\). The primers were synthesized by Shanghai Bio-Chemical Corporation.

**DHPLC analysis**

The amplified PCR fragments were screened for sequence variants by denaturing high pressure liquid chromatography (DHPLC) on a WAVE DNA fragment analysis system (Transgenomic, San Jose, CA, USA). The running conditions for each amplicon (available upon request) were determined by the Waverunner 3.4.4 software (Transgenomic, San Jose, CA, USA) based on the DNA sequence. Five mL of each PCR product (containing 50-100 ng of DNA) was denatured at 95°C for 3 min and then gradually reannealed by decreasing the sample temperature from 95°C to 65°C over 30 min. PCR products were then separated at a flow rate of 0.9 mL/min with a linear acetonitrile gradient. Generally, analysis took approximately 10 min including column regeneration and re-equilibration to starting conditions. The column mobile phase consisted of a mixture of 0.1 mol/L triethylamine acetate (pH 7.0) with (buffer B) or without (buffer A) 25% acetonitrile. Samples displaying variant elution peaks in each run were chosen for sequence analysis. For some amplicons displaying variations in elution profiles of control samples, all samples were sequenced.

**RESULTS**

Among the 5 probands of the five Chinese HNPCC kindreds, 180 PCR products were screened by DHPLC. Two PCR products found with variant elution peaks by DHPLC were identified to have mutations. One was hMSH2 c.1808A→G resulting in Asp 603 Gly identified in the HNP5 kindred’s proband and tested among the family members (Figures 1-3). The other was hMLH1 c.1882A→G identified in the HNP2 kindred’s proband (Figures 4 and 5), which was not tested among the family members, because it might be the nonsense mutation analyzed by BLAST.

As shown in Figure 3, in the HNPCC5 kindred, there were four colorectal carcinoma patients in two successive generations, and three of these were diagnosed before the age of 45 years. The proband developed endometrial carcinoma at the age of 61 years, bladder carcinoma at the age of 66 years and colorectal carcinoma at the age of 72.
years, while his father developed bladder carcinoma at the age of 70 years. In addition, patient III-1 had colorectal carcinoma at the age of 34 years and died of synchronous hepatic metastasis.

In the HNP5 kindred, each PCR product from nine proband's family members was tested by direct DNA sequencing. Only three of them were found to have the missense mutation in hMSH2 at position A1808G. The missense mutation sequence variant was found in exon 12 of hMSH2 gene. It was a single nucleotide substitution of c.1808A→G (Figure 2), which resulted in Asp 603 Gly of hMSH2 (NCBI Ref. Seq. NM 000251 and NP 000242 for mRNA and protein, respectively). Proband and patient III-4 and -5 had this mutation and developed colorectal carcinoma. Patient III-1’s daughter had no colorectal disease even though she had this mutation, and was still under follow-up. No mutation was found in the others.

DISCUSSION

CRC is one of the most common cancers and its clinical selection criteria for cancer families were first established in Amsterdam in 1990 by the International Collaborative Group on HNPCC and modified in 1999[14]. Detection of constitutional mutations in genes associated with predisposition to cancer is practical in molecular diagnosis. Data suggest that molecular testing is much more efficient, if analyses are focused on a limited number of alterations[6,12]. Detection of germline mutation carriers is an efficient method to define high-risk CRC patients. Identification of germline mutations of either hMSH2 or hMLH1 could be performed in 50%–70% of families meeting the Amsterdam criteria for HNPCC, whereas the families not complying with these criteria show a much lower frequency of the MMR gene mutations[14,17]. Thus, hMSH2 or hMLH1 gene testing is most often used in early diagnosis of at-risk family members with HNPCC.

To identify a population-specific panel of mutations, it is crucial to describe them in all ethnic groups.

Even though CRC is common in China, few studies on HNPCC pedigree and its predisposition gene are available[4,17]. In our study, HNPCC kindreds were collected and hMSH2 and hMLH1 gene mutations were tested in order to find high-risk CRC populations. Two mutations were found among the five Chinese HNPCC kindreds. In the 5HNPCC kindreds, missense mutation was found in four members, three of them developed colorectal carcinoma. Although it has not been confirmed as a germline mutation yet, it may be an important factor for CRC development. Thus, the patient III-1’s daughter with this mutation should be closely followed up.

Approximately 20% of patients with colorectal cancer have a genetic component and HNPCC is the most common autosomal dominant hereditary syndrome predisposing to colorectal cancer[18,19]. Various methods have been described to screen for HNPCC and directly test for mismatch repair gene mutations[20,21]. For patients with available tumor specimens, MSI and IHC are widely performed. Ruszkiewicz et al[22] reported that immunohistochemistry is an alternative method for assessment of MSI status, which is fast and relatively inexpensive compared with MSI testing. Some reports[22,23,24] suggest that detection of MSI and IHC for hMSH2/hMLH1 proteins is a reliable pre-screening test for hMLH1/hMSH2 germline mutations in families suspected of having HNPCC. Because China is a developing country with a large population and the incidence rate of CRC

www.wjgnet.com
increases, a screening protocol specific for the Chinese population is necessary to detect the high-risk populations with HNPCC. hMSH2 and hMLH1 gene mutation testing is a practical method for detecting HNPCC in Chinese population. Meanwhile, further research should be performed in Chinese HNPCC kindreds with germline mutations.

**COMMENTS**

**Background**
Approximately 20% of colorectal cancer patients have a genetic component and hereditary non-polyposis colorectal cancer (HNPCC) is the most common autosomal dominant hereditary syndrome predisposing to colorectal cancer. Various methods have been described to screen for HNPCC and directly test for mismatch repair gene mutations. Even though CRC is common in China, few studies on HNPCC pedigree and its predisposition gene are available.

**Research frontiers**
Data suggest that molecular testing is much more efficient when analyses are focused on a limited number of alterations. Detection of germline mutation carriers is an efficient method to define high-risk CRC patients. Germline mutations of either hMSH2 or hMLH1 can be identified in 50%-70% of families meeting the Amsterdam criteria for HNPCC. Thus, hMSH2 or hMLH1 gene testing is most often used in early diagnosis of at-risk family members with HNPCC.

**Innovations and breakthroughs**
Five independent Chinese kindreds with HNPCC fulfilling the classical Amsterdam criteria were collected. Mutations were identified in two Chinese HNPCC kindreds. One was the missense mutation of hMSH2 c.1808A→G resulting in Asp 603 Gly, the other was the mutation of hMLH1 c.1882A→G.

**Applications**
Molecular pathological tests should be performed in order to identify individuals and at-risk family members with HNPCC. Close follow-up and intensive surveillance should be performed.

**Terminology**
Denaturing high-performance liquid chromatography (DHPLC) is a method for separating DNA duplexes that differ in the identity of one or more base pairs. The method is believed to be most efficient at the site of mutation. Basic local alignment search tool (BLAST) is powerful to compare novel sequences with previously characterized genes. Both functional and evolutionary information can be obtained from well designed queries and alignments. BLAST 2.0 can rapidly search for nucleotide and protein in their databases.

**Peer review**
The results of this clinical study indicate that mutation testing for hMSH2 and hMLH1 by PCR and direct sequencing is a preferable method to identify high-risk HNPCC patients.

**REFERENCES**
1. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999; 116: 1453-1456
2. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Pelтомаки P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96: 261-268
3. Pelтомаки P, Vasen H. Mutations associated with HNPCC predisposition -- Update of ICG-HNPPC/INSIGHT mutation database. *Dis Markers* 2004; 20: 269-276
4. Zhang CH, He YL, Zhan WH, Cai SR, Huang MJ, Wang JP, Chen CQ. Hereditary nonpolyposis colorectal cancer: an analysis of 11 kindreds. *Zhongguo Shiyan Waike Za Zhi* 2005; 22: 222-224
5. He YL, Zhang CH, Huang MJ, Cai SR, Zhan WH, Wang JP, Wang JF. Clinical analysis of eight kindreds of familial adenomatous polyposis. *World J Gastroenterol* 2010; 16: 3659-3661
6. Holinski-Feder E, Muller-Koch Y, Friedl W, Moeslein G, Keller G, Plaschke J, Ballhausen W, Gross M, Baldwin-Jedele K, Jungck M, Mangold E, Vogelsang H, Schackert HK, Loehse P, Murken J, Meitinger T. DHPLC mutation analysis of the hereditary nonpolyposis colon cancer (HNPCC) genes hMLH1 and hMSH2. *Biochem Biophys Methods* 2001; 47: 21-32
7. Kurzawski G, Safranow K, Suchy J, Chlubek D, Scott RJ, Lubinski J. Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography. *J Biochem Biophys Methods* 2002; 51: 89-100
8. O’Donovan MC, O’Neill PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C, Spight G, Upadhyaya M, Sommer SS, McGuffin P. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. *Genomics* 1998; 52: 44-49
9. Nyström-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Jarvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B. Founding mutations and Alu-mediated recombination in hereditary colon cancer. *Nat Med* 1995; 1: 1203-1206
10. de la Chapelle A. 2002 William Allan Award Address. Inherited human diseases: victories, challenges, disappointments. *Am J Hum Genet* 2003; 72: 236-240
11. Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. *Cancer* 2002; 95: 1848-1856
12. Hadley DW, Jenkins J, Dimond E, Nakahara K, Grogan L, Liewehr DJ, Steinberg SM, Kirsch I. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. *Arch Intern Med* 2003; 163: 573-582
13. Akiyama Y, Sato H, Yamada T, Nagasaki H, TsuChiya A, Abe R, Yusa Y. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. *Cancer Res* 1997; 57: 3920-3923
14. Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. *J Med Genet* 2000; 37: 641-645
15. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colorectal cancer. *Cell* 1993; 75: 1027-1038
16. Mitchell RJ, Farrington SM, Dunlop MG, Campbell H. Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. *Ann J Epidemiol* 2002; 156: 885-902
17. Chan TL, Chan YW, Ho JW, Chan C, Chan AJ, Chan E, Lam PW, Tse CW, Lee KC, Lau CW, Gwi E, Leung SY, Yuen ST. MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. *Am J Hum Genet* 2004; 74: 1035-1042
18. Watson P, Lynch HT. Cancer risk in mismatch repair gene carriers. *Fam Cancer* 2001; 1: 57-60
19. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Pel'tomak P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 1999; 81: 214-218
20. Hoedema R, Monroe T, Bos C, Palmer S, Kim D, Marvin M, Luchtefeld M. Genetic testing for hereditary nonpolyposis colorectal cancer. *Am Surg* 2003; 69: 387-391; discussion 391-392
21. Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, Orntoft TF. Antibody-screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. *Cancer* 2002; 95: 2422-2430
consent for tumour testing in HNPCC. Clin Genet 2007; 71: 400-405

23 Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-928

24 Tomlinson IP, Ilyas M, Bodmer WF. Allele loss occurs frequently at hMLH1, but rarely at hMSH2, in sporadic colorectal cancers with microsatellite instability. Br J Cancer 1996; 74: 1514-1517

25 Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80

26 Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, Orntoft TF. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer 2002; 95: 2422-2430

27 Rigau V, Sebbagh N, Olschwang S, Paraf F, Mourra N, Parc Y, Flejou JF. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 (correction of hMLH6) immunostaining. Arch Pathol Lab Med 2003; 127: 694-700

28 Ruszkiewicz A, Bennett G, Moore J, Manavis J, Rudzki B, Shen L, Suthers G. Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology 2002; 34: 541-547

29 Hendriks Y, Franken P, Dierssen JW, De Leeuw W, Wijnen J, Dreef E, Tops C, Breuning M, Brocker-Vriends A, Vasen H, Fodde R, Morreau H. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003; 162: 469-477

30 Umar A, Boland CR, Tardiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jess J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268

S- Editor Zhu LH  L- Editor Wang XL  E- Editor Liu Y